ENTX — Entera Bio Ltd.
Is ENTX overbought or oversold? Here is the current MarketMoodz read.
Entera Bio Ltd. (ENTX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.02. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$3.02
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Entera Bio Ltd. (ENTX) is a small-cap biotech with limited visible filings and no social/research momentum in the data provided. Financial health and cash runway are unclear, making the company dependent on clinical/regulatory catalysts or partnership announcements to drive material upside. Market positioning is typical of early-stage biotech: high upside on successful milestones but significant downside risk from trial failures, financing dilution, and competitive pressure. Sector flows currently favor large-cap, defensive pharma, which reduces investor appetite for microcap biotech exposure. Absent near-term positive news (data readouts, strategic partner, or clear financing), the company is likely to remain volatile with downside risk; a successful catalytic event or non-dilutive financing would materially change the outlook.
Key factors
- Limited public disclosure and no recent EDGAR detail provided, creating uncertainty around cash runway and near-term financing needs
- Business outcome likely binary and highly dependent on clinical/regulatory milestones and any near-term data readouts or partnerships
- Sector trends favor large-cap pharma and defensive healthcare flows, which can reduce investor appetite for small-cap biotechs without clear catalysts
- Convertible-debt and financing environment in biotech/diagnostics raises the risk of dilution and hedging pressure for smaller issuers
- Low visible social sentiment and research coverage increase liquidity risk and potential for outsized moves on sparse news
Risks
- Clinical or regulatory setbacks for pipeline assets that could materially reduce valuation
- Need for dilutive equity or convertible financing in the near term if cash runway is short
- Low trading liquidity and wide bid/ask spreads causing elevated volatility on limited news
- Competition from larger pharma companies and alternative technologies that could limit commercial prospects
- Reimbursement, commercialization and market-access challenges if products advance to market
- Broader sector derisking or rotation away from small biotech names in the absence of positive catalysts
See today's live rating, score and targets
Members see the live hourly rating for ENTX — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.